The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
For a start Dvrg are promoting Avacta via their Wastewater technology, they are Not using Affimers for their Breath Test it's Aptamers . Their breath Test is Not a 4 sec test, it's the Wastewater technology than can detect the virus in 4 seconds. The potential in detecting the virus quickly in Wastewater and locating the source is massive imo. It is important to state facts and they can be easily found if there is a will.
Rollyroll Affimers are not used in the breath test, the reagent will be an Aptamer. The collaboration between Avacta / Dvrg is for Affimers to be used in wastewater only. Aptamers are also used in wastewater detection as well. The Avacta results indicate sensitivity levels using Affimers is better than Aptamers for a Lateral Flow Test. Could be both are used by Dvrg, we will know shortly. Wastewater side of the business should get some well deserved recognition soon.
Just counted 12 Companies which manufacture LFTs in America, Danaher being one of these listed. No need to name the rest as Avacta / Cytiva /Danaher is all we need. The remaining prominent players in Europe include Hoffmann-La Roche Switz, Siemens Germany, Qiagen Holland, Bio Porto Denmark. Cytiva have sites in Germany and China producing all the necessary items to manufacture LFTs and Cytiva have a CONTRACT with us providing Affimers , we will have the best reagent in any validated LFD. What manufacturing company would not be knocking themselves out to get a piece of this business. The LFT business generated $8.7 billion in America in 2017, Covid will blow this figure out the water. The question is can we produce enough of these gold coated Affimers to keep up with demand. Happy Days.
Danaher own Beckman and Cytiva, Beckman join up with genedrive to do the selling after Cytiva improve their PCR test. Would it not be logical for Danaher to find a large manufacturer for the Cytiva / Avacta partnership . The clout Danaher has and the prospect of capturing a very lucrative market with Cytiva / Avacta is a no brainer. The potential profit margins are immense, imo they would be crazy not to be part of this.
Cytiva have sites in Europe and Asia which all fits well into the overall plan of global manufacturing. I would not write off Cytiva being a major driving force in the plan set out by the CEO from the start. Cytiva recognise the need for quick diagnostic testing and are investing heavily in Europe / Asia to satisfy what they see as a massive growth market. They have improved the timescale in PCR testing for genedrive and their belief in LFDs playing a major role in controlling Covid has not changed. The more this picture develops it highlights the outstanding vision the CEO has shown. It was stated from the beginning we had one shot at producing the best test and he has delivered without question. There was a plan to expand manufacturing World wide and this is the role Cytiva are now playing imo. Someone asked why send our LFD to Europe for validation, apparently our partner has a very good answer to this question. Cytiva have also played a major role in the growth of Danaher a multi billion $ company, their involvement with us should not be underestimated. Finally the statement, our only worry will be satisfying demand says it all.
It was stated in the Mologic update we were seeking partners abroad too increase capacity. Frustration may have been a factor in spreading the validation process further afield however it could also be viewed as a very good piece of business nous on his part. One of the largest producers of LFDs in Europe is OPERON, over 20 years experience in this field and they have a LFD to detect PSA levels in men using Antibodies as the reagent. There will be other companies who will be very interested in our Affimer technology and the potential to manufacture in mass. This is a chance to show case our potential in this market not only for Covid. The only down side is the EU are even slower in grasping a situation that requires understanding and the common sense to act quickly. We can only live in hope, lets see how this pans out.
Mologic have bought into the theory Affimers are the future for Biosensors. All the evidence points to to the fact Affimers work, if you close your eyes to the potential market outside Covid the SP will reflect this. The overall market for Rapid POC Biosensors is massive, mind blowing. The potential to produce an LFD for many diseases highlights how far Avacta can take this technology. Name any disease that will benefit from Rapid POC testing and you have a winner, not only in humans. Sepsis is being targeted, a disease that kills around 44,000 people a year in the UK and requires rapid diagnosis , the list is endless. As said many times over and over, everyone producing LFDs has three choices of reagent. Listening to the CEO in regards to the Mologic deal, they seem to think we have WINNER ! Looking beyond Covid the future looks pretty good to me.
Rambling seems to be your forte Cautious, well presented factual comments. Found it rather sad Custom delays playing a part in the validation process, better not upset our EU friends again. Do they claim to have a contract with Avacta demanding two million LFD tests a day are to be highjacked at the border. The Financial Times will no doubt keep us well misinformed. Happy days ahead.
Just trapped 2 million haggi in one day, anyone know of a reliable media source to report my fantasy achievement. To my knowledge HMG have ordered 2 million SureScreen tests, a one of order which may be increased at a later date. What planet do these purveyors of crap live, SIXTY MILLION TESTS PER MONTH to be delivered by the star ship FANTASY. The manufactures mentioned in this monumental task will be extremely pleased to have been nominated for such a task. Monday morning should be interesting.
Innova like many LFDs was being evaluated by Porton Down & co around Aug time, launched in November because it was the only test that could provide the number of tests required. It was and is successful in detecting high viral loads in the range recommended (CT< 25 ). Say for arguments sake a three month turn around , Avacta is being judged on timescale by their collaboration with Cytiva. Nothing to report since May 2020 when Cytiva received the desired Affimers . Avacta switch tack and announce a deal with BBI on 10th Aug , a Sovereign test with a company who claim on their website. " Using high quality raw materials we will rapidly take your assay from concept to creation , supporting you through development & manufacturing." That has taken from Aug - Nov to cover the above BBI remit, plus validation in the Lab., a very impressive achievement. If it took Innova three months to pass through Porton Down how is it possible for Avacta to accomplish this validation process in six weeks. The Cytiva input is no longer valid for whatever reason and if you look at the timescale from Avacta / BBI working as a unit imo where is the delay. The Avacta / Cytiva deal is water under the bridge, we are well on track with all the Sovereign Companies involved .
Attempting to explain a chain of events that demonstrates dates ,timescales etc play a vital role in the research of this virus.
Gsk & Vir Biotechnology collaborate in finding a neutralising therapy for Covid, GSK funding $250 million, date early 2020. The method used was Monoclonal Antibodies a well established binder.
Avacta confirm they have produced Affimers that will neutralise the virus and are looking for a partner to collaborate with. This was in June 2020, and to my knowledge had no takers. GSK & co already involved using Antibodies.
Early in October Affimers demonstrate non Antibody binding proteins provide an ADVANTAGE over current Antibody based detection systems.
Feb 2021 GSK & co discover Antibodies are failing against variants of the virus . They were chosen at the TIME to target the spike protein , in general the virus mutation does not change it's binding method or it will not attach to the cell. This virus makes a change that helps it bind to the cell even better so Monoclonal Antibodies are lost.
Through no fault of Avacta Affimers have been shown to be better than Antibodies in many ways and have not been utilised to their full potential in providing an effective neutralising therapy to Covid.
Now GSK, lilly, and Vir Biotechnology are combining Antibodies to find a way ahead. Unbelievable, we are way under the radar for whatever reason. Please try and shoot holes in the above course of events, I can find none other than we are a small fish in a large Ocean.
Being Scottish we are not all in favour of independence as many think south of the border AgentB. Your assumption of not going ahead with the Lab in Scotland has a nothing to do with politics. The testing capacity it would have provided was for PCR and as we all know probably not required now. As simple as that.
Covid is relentless and has over shadowed the potential of BAMs. We issue an RNS on the collaboration of Bruker / Adeptrix / Avacta and it is lost to a virus that has taken over our lives. BAMs reaches far beyond the virus and imo will be the beginning of a very exciting period for Avacta. Careful reading of the comments made by Adeptrix / Bruker demonstrates the vast potential of this merger.
Adeptrix state, BAMs was able to monitor the TAU protein in cerebrospinal fluid & brain tissue to distinguish between normal & diseased tissue. By studying thousands of samples per day they can be analysed quickly and converted to a rapid test. Guess who has an Affimer for the TAU protein. Alzheimers has a correlation with the TAU protein, a potential rapid test for this terrible disease.
Bruker state, our partnership is expected to accelerate collaborations with Antibodies & other Affinity reagents. Affi BAMs could well be an omen.
BAMS is also used in the study of Cardiovascular Disease, the C- Reactive Protein (CPR ) is found to correlate with this disease, Avacta have an Affimer for this as well, who would believe it. In associating BAMs solely with covid the potential of this powerful tool has been totally overlooked .The CEO has guided this Company with great vision imo. Antibody mimics are the future and we have one all to ourselves, where do Affimers pop up next in the BAMs story. Exciting times ahead.
PAHO there claim to have the the best performance was in relation to their LFD as I read it. To claim they have the top performing test using magnification is surely a false statement imo. Irrespective of what it is Avacta will produce a test that will do very well.
Agree Braveheart / Paraytec trials have been delayed however their claim to have the market leader in performance levels of the test is interesting. They claim it will pick up viral loads of < Ct 31 which is way better than all the tests validated so far . The agreed figure of < Ct 25 to achieve > 90% Sensitivity validates this claim. This test will pick up people with much lower viral loads and maybe the benchmark of < Ct 25 can be improved . Avacta have said their test was within the viral load requirement, maybe they have been trying to achieve the figures claimed by Braveheart all along. Hence the delay and hopefully they have achieved their gaol. In the end everybody will sell their product, it's the old battle Affimers v Aptamers.
Bruker will not dilly dally in obtaining FDA approval, the yanks are all about the mighty $, if they sniff a profit it will be rolled out very quickly. CE marking imo will play second fiddle to the impact this will have in America, trying to locate a comment I read this morning where the CEO of Bruker said we will roll this out as quickly as we can. Why is BBI reported to be purchasing extra tooling, is it for one of these foreign tests or a home made variety!
Even better if you listen from 04-25 secs , he says the values derived over novel cancer therapies EXCEED that of Covid rapid testing. Quite a statement from the CEO , we are only a month down the line from the last update covering Christmas / New year holidays. Outstanding news, thereafter no news is good news imo, if you think moving from very good trials in the Lab will develop into failure in the clinical tests then it's time to assess your position. My thought process always returns to, "The Affimers provided were a potent binder to the Covid virus". Happy days ahead for me.
Muck had a check on the Daewoong website and the DWP710 listed trial showed no partners in this venture. It would be really surprising if Avacta were involved and not listed. Hope I am wrong , can't find anything to support DWP710 / Avacta involvement.
Avacta's only involvement with Daewoong in relation to Covid is a Stem Cell therapy treatment for people with Long Covid as far as I know. A treatment to repair damaged lungs not a neutralising therapy. The only other area where Affimers are employed is the treatment for Autoimmune & inflammatory diseases ( Crones disease, MS ). AffyXell / Avacta collaboration fully funded by Daewoong, Avacta own 45% of this venture. Great deal at no cost, a slap on the back for the CEO imo.
Thought I would try that revolutionary new method of Google you mentioned PL75, astounding Roche, Surescreen use Aptamers as a reagent. The remaining tests are not so forthcoming in sharing their information on this subject, nothing new. Rapid Flow POC LFDs using Antibodies as a reagent would imo be a non starter. The disadvantages of using Antibodies as stated by sleepydave is spot on. Antibody mimics are the way ahead to develop POC Diagnostics.